CANCER BUZZ TV

In this episode, CANCER BUZZ speaks with Jean Louise Koff, MD, MSc, associate professor of hematology and medical oncology at Winship Cancer Institute of Emory University, to discuss the impact of bispecific antibodies on cancer treatment outcomes, and the challenges and opportunities of integrating this innovative approach into community oncology practices.

In this episode, CANCER BUZZ speaks with Jeff Sharman, MD, medical director of hematology research, US Oncology, and director of research, Willamette Valley Cancer Institute, about the role of biomarker testing in guiding treatment decisions and how evidence-basedmanagement of treatment-related adverse events can serve this patient population.

In this episode, CANCER BUZZ speaks with Nirav Shah, MD, MSHP, associate professor of medicine at Medical College of Wisconsin and Kirollos Hanna, PharmD, BCOP, PCOP, FACCC, assistant professor of pharmacy at Mayo Clinic and director of pharmacy at Minnesota Oncology, about shared decision making in the management of relapsed or refractory mantle cell lymphoma.

In this episode, CANCER BUZZ speaks with Karen Fancher, PharmD, BCOP, clinical pharmacy specialist in oncology at University of Pittsburgh – Passavant Hospital, and Victoria Nachar, PharmD, BCOP, clinical pharmacist specialist in ambulatory hematology and adjunct clinical instructor at the University of Michigan, about strategies to address common adverse events experienced by patients with mantle cell lymphoma.

In this episode, CANCER BUZZ speaks with Jean Louise Koff, MD, MSc, associate professor at Emory University School of Medicine in Atlanta, Georgia, about fostering trust, rapport, and collaboration in the patient-provider relationship.

In this episode, CANCER BUZZ speaks with David Sallman, MD, associate member in the Department of Malignant Hematology at Moffitt Cancer Center, and Karley Trautman, DNP, ANP-BC, AGACNP-BC, senior instructor of Medical Oncology at Highlands Ranch Cancer Center, to discuss best practices in the management of anemia in low-risk MDS patients.

In this episode, CANCER BUZZ speaks with Steven Gilmore, PharmD, BCOP, Senior Manager of Clinical Content in Pharmacy and Clinical Programs with McKesson Specialty Health, and Christopher Benton, MD, hematologist and medical oncologist at Rocky Mountain Cancer Centers, to review key considerations and emerging trends for the treatment of anemia in the low-risk MDS population.

In this episode, CANCER BUZZ speaks with Amy DeZern, MD, MHS, director, Bone Marrow Failure and MDS Program, Johns Hopkins University School of Medicine in Baltimore, Maryland; Donald Moore, PharmD, BCPS, BCOP, DPLA, FCCP, clinical oncology pharmacy manager, Atrium Health Levine Cancer in Charlotte, North Carolina; and David Sallman, MD, assistant member, Department of Malignant Hematology, Moffitt Cancer Center in Tampa, Florida. Their discussion elucidates an array of patient-centered approaches, touches on social determinants of health, and highlights collaborative measures to support care coordination in the management of anemia in patients with high-risk myelodysplastic syndrome and acute myeloid leukemia.

Coordination of care for patients diagnosed with acute myeloid leukemia, particularly those who are ineligible for transplant, can impact access to specialist care, clinical trials, and cancer programs with advanced capabilities to treat patients with acute myeloid leukemia.

In this episode, CANCER BUZZ speaks with Farrukh T. Awan, MD, MS, professor of Internal Medicine and director of Lymphoid Malignancies at the Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, about their approach to addressing regional barriers to improve care for patients with chronic lymphocytic leukemia.

Personalizing care goals to account for a patient’s values, preferences, or circumstances can make a significant difference in shared decision-making and treatment planning. In this episode, CANCER BUZZ speaks with Melissa Kah Poh Loh, MBBCh, BAO, assistant professor of Geriatric Hematology and Oncology at the University of Rochester Medical Center’s Wilmot Cancer Institute about strategies to optimize critical conversations with patients with acute myeloid leukemia.

While there are many factors why patients with acute myeloid leukemia are ineligible for allogeneic stem cell transplant, such as age, financial hurdles, or other comorbidities, these factors are often compounded by social determinants of health, which can act as a significant barrier to consolidation therapy and long-term remission for these patients. In this episode, CANCER BUZZ speaks with Keri Maher, DO, Director of the Acute Leukemia Program, and assistant professor at Virginia Commonwealth University’s Massey Cancer Center about strategies to address these disparities and optimize care and treatment options for patients with acute myeloid leukemia who do not receive a transplant.

Learn how recent guideline and treatment options by the National Comprehensive Cancer Network (NCCN) can optimize care for patients with MPNs.

As myeloproliferativeneoplasms (MPNs) carry a significant symptom burden and oftentimes can requirelifelong care coordination and close monitoring, hear how a strongmultidisciplinary approach can impact shared decision-making and patientengagement.

CANCER BUZZ speaks with Srdan Verstovsek, MD, PhD, about when to begin therapeutic care for myeloproliferative neoplasms (MPNs) and the urgency of treatment.

Learn about a nurse’s role in care planning, and engaging patients in education, and shared decision making for treatment goals and planning.

Hear why community practices need to monitor symptoms carefully and about a new tool that can help assess symptoms more accurately and help care teams form treatment plans.

Caring for patients with acute myeloid leukemia (AML) depends on many factors and can vary as much as the patients themselves.

Three clinicians discuss their experiences with difficult conversations on the relative risks and benefits around treatment decisions in this rapidly evolving environment.

Three specialists in multiple myeloma care share their experiences that may help other providers and patients move smoothly through this time of transition while maintaining high quality care.